Howard Trachtman

List of Publications by Year
in descending order

147 papers	6,862 citations	70961 41 h-index	64668 79 g-index
153 all docs	153 docs citations	153 times ranked	8061 citing authors

#	Article	IF	Citations
1	APOL1 Genetic Variants in Focal Segmental Glomerulosclerosis and HIV-Associated Nephropathy. Journal of the American Society of Nephrology: JASN, 2011, 22, 2129-2137.	3.0	713
2	Soluble Urokinase Receptor and Chronic Kidney Disease. New England Journal of Medicine, 2015, 373, 1916-1925.	13.9	338
3	Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. ELife, 2015, 4, e06315.	2.8	271
4	Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney International, 2013, 83, 749-756.	2.6	268
5	Management of Childhood Onset Nephrotic Syndrome. Pediatrics, 2009, 124, 747-757.	1.0	247
6	A phase 1, single-dose study of fresolimumab, an anti-TGF-Î² antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney International, 2011, 79, 1236-1243.	2.6	222
7	Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney International, 2011, 80, 868-878.	2.6	208
8	KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis. American Journal of Kidney Diseases, 2013, 62, 403-441.	2.1	204
9	Circulating suPAR in Two Cohorts of Primary FSGS. Journal of the American Society of Nephrology: JASN, 2012, 23, 2051-2059.	3.0	202
10	Non-enteropathic hemolytic uremic syndrome: causes and short-term course. American Journal of Kidney Diseases, 2004, 43, 976-982.	2.1	198
11	Effect of an Oral Shiga Toxinâ€“Binding Agent on Diarrhea-Associated Hemolytic Uremic Syndrome in Children<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2003, 290, 1337.	3.8	187
12	Renal and neurological involvement in typical Shiga toxin-associated HUS. Nature Reviews Nephrology, 2012, 8, 658-669.	4.1	179
13	Alternative Pathway of Complement in Children with Diarrhea-Associated Hemolytic Uremic Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1920-1924.	2.2	167
14	The effects of environmental chemicals on renal function. Nature Reviews Nephrology, 2015, 11, 610-625.	4.1	163
15	Critical and Honest Conversations. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1664-1672.	2.2	157
16	Urinary Phthalates Are Associated with Higher Blood Pressure in Childhood. Journal of Pediatrics, 2013, 163, 747-753.e1.	0.9	128
17	DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. Journal of the American Society of Nephrology: JASN, 2018, 29, 2745-2754.	3.0	128
18	Association of Histologic Variants in FSGS Clinical Trial with Presenting Features and Outcomes. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 399-406.	2.2	125

#	Article	IF	Citations
19	Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial. Journal of the American Society of Nephrology: JASN, 2015, 26, 1443-1448.	3.0	104
20	Exposure to bisphenols and phthalates and association with oxidant stress, insulin resistance, and endothelial dysfunction in children. Pediatric Research, 2017, 81, 857-864.	1.1	102
21	Bisphenol A exposure is associated with low-grade urinary albumin excretion in children of the United States. Kidney International, 2013, 83, 741-748.	2.6	96
22	Urinary exosomal Wilms' tumor-1 as a potential biomarker for podocyte injury. American Journal of Physiology - Renal Physiology, 2013, 305, F553-F559.	1.3	96
23	Urinary polycyclic aromatic hydrocarbons and measures of oxidative stress, inflammation and renal function in adolescents: NHANES 2003â€“2008. Environmental Research, 2016, 144, 149-157.	3.7	90
24	Association between perfluoroalkyl acids and kidney function in a cross-sectional study of adolescents. Environmental Health, 2015, 14, 89.	1.7	86
25	Interstitial fibrosis scored on whole-slide digital imaging of kidney biopsies is a predictor of outcome in proteinuric glomerulopathies. Nephrology Dialysis Transplantation, 2018, 33, 310-318.	0.4	85
26	Phase 1 Trial of Adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) Study Group. American Journal of Kidney Diseases, 2010, 55, 50-60.	2.1	73
27	Organoid single cell profiling identifies a transcriptional signature of glomerular disease. JCI Insight, 2019, 4, .	2.3	73
28	Clinical trial of extended-release felodipine in pediatric essential hypertension. Pediatric Nephrology, 2003, 18, 548-553.	0.9	72
29	CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. American Journal of Kidney Diseases, 2019, 73, 218-229.	2.1	68
30	Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group. BMC Nephrology, 2015, 16, 111.	0.8	63
31	Dietary Phthalates and Low-Grade Albuminuria in US Children and Adolescents. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 100-109.	2.2	59
32	An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 414-421.	2.2	57
33	Complement Activation in Patients with Focal Segmental Glomerulosclerosis. PLoS ONE, 2015, 10, e0136558.	1.1	54
34	Complete Remission in the Nephrotic Syndrome Study Network. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 81-89.	2.2	53
35	Renal Function and exposure to Bisphenol A and phthalates in children with Chronic Kidney Disease. Environmental Research, 2018, 167, 575-582.	3.7	53
36	Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. Kidney International, 2011, 79, 678-685.	2.6	52

#	Article	IF	Citations
37	Focal Segmental Glomerulosclerosis and Chronic Kidney Disease in Pediatric Patients. Advances in Chronic Kidney Disease, 2011, 18, 332-338.	0.6	51
38	Glyphosate exposures and kidney injury biomarkers in infants and young children. Environmental Pollution, 2020, 256, 113334.	3.7	50
39	The impact of disease duration on quality of life in children with nephrotic syndrome: a Midwest Pediatric Nephrology Consortium study. Pediatric Nephrology, 2015, 30, 1467-1476.	0.9	49
40	Association of Serum Soluble Urokinase Receptor Levels With Progression of Kidney Disease in Children. JAMA Pediatrics, 2017, 171, e172914.	3.3	46
41	Mutation Conferring Apical-Targeting Motif on AE1 Exchanger Causes Autosomal Dominant Distal RTA. Journal of the American Society of Nephrology: JASN, 2012, 23, 1238-1249.	3.0	44
42	Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis. Kidney International Reports, 2020, 5, 494-502.	0.4	43
43	Increased urinary nitrite excretion in children with minimal change nephrotic syndrome. Journal of Pediatrics, 1996, 128, 173-176.	0.9	41
44	Recurrent focal segmental glomerulosclerosis after kidney transplantation. Pediatric Nephrology, 2015, 30, 1793-1802.	0.9	40
45	Serially assessed bisphenol A and phthalate exposure and association with kidney function in children with chronic kidney disease in the US and Canada: A longitudinal cohort study. PLoS Medicine, 2020, 17, e1003384.	3.9	39
46	Health-related quality of life in glomerular disease. Kidney International, 2019, 95, 1209-1224.	2.6	38
47	Involvement of the fractalkine pathway in the pathogenesis of childhood hemolytic uremic syndrome. Blood, 2007, 109, 2438-2445.	0.6	36
48	Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET). Kidney International Reports, 2017, 2, 654-664.	0.4	36
49	Phase I Trial of Rosiglitazone in FSGS. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 39-47.	2.2	34
50	Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design. BMC Nephrology, 2011, 12, 8.	0.8	34
51	Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group. BMC Nephrology, 2010, 11, 2.	0.8	32
52	HUS and TTP in Children. Pediatric Clinics of North America, 2013, 60, 1513-1526.	0.9	32
53	Novel Therapies for FSGS: Preclinical and Clinical Studies. Advances in Chronic Kidney Disease, 2015, 22, e1-e6.	0.6	31
54	An international cohort study of autosomal dominant tubulointerstitial kidney disease due to mutations identifies distinct clinical subtypes. Kidney International, 2020, 98, 1589-1604.	2.6	27

#	Article	IF	Citations
55	Organophosphate pesticides and progression of chronic kidney disease among children: A prospective cohort study. Environment International, 2021, 155, 106597.	4.8	26
56	Is There Clinical Value in Measuring suPAR Levels in FSGS?. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1273-1275.	2.2	24
57	Patient-Reported Outcomes in Glomerular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 140-148.	2.2	24
58	Hypokalemia Associated With a Claudin 10 Mutation: A Case Report. American Journal of Kidney Diseases, 2019, 73, 425-428.	2.1	24
59	Proteinuria Reduction and Kidney Survival in Focal Segmental Glomerulosclerosis. American Journal of Kidney Diseases, 2021, 77, 216-225.	2.1	23
60	Cisplatinum nephrotoxicity in oncology therapeutics: retrospective review of patients treated between 2005 and 2012. Pediatric Nephrology, 2014, 29, 2421-2424.	0.9	21
61	Randomized Clinical Trial Design to Assess Abatacept in Resistant Nephrotic Syndrome. Kidney International Reports, 2018, 3, 115-121.	0.4	21
62	Treatment of Recurrent Focal Segmental Glomerulosclerosis in Pediatric Kidney Transplant Recipients: Effect of Rituximab. Journal of Transplantation, 2011, 2011, 1-5.	0.3	20
63	Contribution of Renal and Nonâ€Renal Clearance on Increased Total Clearance of Adalimumab in Glomerular Disease. Journal of Clinical Pharmacology, 2013, 53, 919-924.	1.0	20
64	Renal Function and Proteinuria after Successful Immunosuppressive Therapies in Patients with FSGS. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 211-218.	2.2	19
65	Responsiveness of the PROMISÂ® measures to changes in disease status among pediatric nephrotic syndrome patients: a Midwest pediatric nephrology consortium study. Health and Quality of Life Outcomes, 2017, 15, 166.	1.0	19
66	Direct Reversible Kidney Injury in Familial Hemophagocytic Lymphohistiocytosis Type 3. Journal of the American Society of Nephrology: JASN, 2015, 26, 1777-1780.	3.0	17
67	The Effect of a Gluten-Free Diet in Children With Difficult-to-Manage Nephrotic Syndrome. Pediatrics, 2016, 138, .	1.0	17
68	Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study. Kidney International Reports, 2020, 5, 1679-1689.	0.4	17
69	Patient Recruitment into a Multicenter Randomized Clinical Trial â€˜for Kidney Disease: Report of the Focal Segmental Glomerulosclerosis Clinical Trial (FSGS CT). Clinical and Translational Science, 2013, 6, 13-20.	1.5	16
70	Using PROMISÂ® to create clinically meaningful profiles of nephrotic syndrome patients.. Health Psychology, 2019, 38, 410-421.	1.3	16
71	Natural antibody and complement activation characterize patients with idiopathic nephrotic syndrome. American Journal of Physiology - Renal Physiology, 2021, 321, F505-F516.	1.3	16
72	Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. American Journal of Kidney Diseases, 2022, 79, 570-581.	2.1	15

#	Article	IF	Citations
73	Treatment of Recurrent Focal Segmental Glomerular Sclerosis Posttransplant With a Multimodal Approach Including High-Galactose Diet and Oral Galactose Supplementation. Transplantation, 2011, 91, e35-e36.	0.5	14
74	Glomerular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1138-1140.	2.2	14
75	Learning to live with nephrotic syndrome: experiences of adult patients and parents of children with nephrotic syndrome. Nephrology Dialysis Transplantation, 2017, 32, i98-i105.	0.4	14
76	Prevalence of low molecular weight proteinuria and Dent disease 1 CLCN5 mutations in proteinuric cohorts. Pediatric Nephrology, 2020, 35, 633-640.	0.9	14
77	The longitudinal relationship between patient-reported outcomes and clinical characteristics among patients with focal segmental glomerulosclerosis in the Nephrotic Syndrome Study Network. CKJ: Clinical Kidney Journal, 2020, 13, 597-606.	1.4	14
78	De novo TRIM8 variants impair its protein localization to nuclear bodies and cause developmental delay, epilepsy, and focal segmental glomerulosclerosis. American Journal of Human Genetics, 2021, 108, 357-367.	2.6	14
79	The Medium Is Not The Message. American Journal of Bioethics, 2008, 8, 9-11.	0.5	12
80	Plasma Zonulin Levels in Childhood Nephrotic Syndrome. Frontiers in Pediatrics, 2019, 7, 197.	0.9	12
81	Adiponectin in children and young adults with focal segmental glomerulosclerosis. Pediatric Nephrology, 2015, 30, 1977-1985.	0.9	11
82	A possible influence of age on absorption and elimination of adalimumab in focal segmental glomerulosclerosis (FSGS). European Journal of Clinical Pharmacology, 2016, 72, 253-255.	0.8	11
83	Early manifestations of renal disease in patients with tuberous sclerosis complex. International Journal of Nephrology and Renovascular Disease, 2017, Volume 10, 91-95.	0.8	11
84	Hemolytic Uremic Syndrome: Toxins, Vessels, and Inflammation. Frontiers in Medicine, 2014, 1, 42.	1.2	10
85	Urinary Epidermal Growth Factor as a Marker of Disease Progression in Children With Nephrotic Syndrome. Kidney International Reports, 2020, 5, 414-425.	0.4	10
86	U.S. Preventive Services Task Force Recommendation and Pediatric Hypertension Screening: Dereliction of Duty or Call to Arms?. Journal of Clinical Hypertension, 2014, 16, 342-343.	1.0	9
87	Text Messaging for Disease Monitoring inÂChildhood Nephrotic Syndrome. Kidney International Reports, 2019, 4, 1066-1074.	0.4	9
88	Emerging drugs for treatment of focal segmental glomerulosclerosis. Expert Opinion on Emerging Drugs, 2020, 25, 367-375.	1.0	9
89	Galactose treatment in focal segmental glomerulosclerosis. Pediatric Nephrology, 2014, 29, 931-931.	0.9	8
90	Oxidant stress and renal function among children with chronic kidney disease: a repeated measures study. Scientific Reports, 2020, 10, 3129.	1.6	8

#	Article	IF	Citations
91	Age-Dependent Definition of CKD. Journal of the American Society of Nephrology: JASN, 2020, 31, 447.1-447.	3.0	7
92	Dynamic treatment regimens in small n, sequential, multiple assignment, randomized trials: An application in focal segmental glomerulosclerosis. Contemporary Clinical Trials, 2020, 92, 105989.	0.8	7
93	Improving data quality in observational research studies: Report of the Cure Glomerulonephropathy (CureGN) network. Contemporary Clinical Trials Communications, 2021, 22, 100749.	0.5	7
94	Regarding Maas's editorial letter on serum suPAR levels. Kidney International, 2012, 82, 492.	2.6	6
95	Allostatic Stress and Inflammatory Biomarkers in Transgender and Gender Expansive Youth: Protocol for a Pilot Cohort Study. JMIR Research Protocols, 2021, 10, e24100.	0.5	6
96	Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulosclerosis Treatment: A Systematic Review and Meta-Analysis. Kidney Medicine, 2022, 4, 100457.	1.0	6
97	Pilot Study of Mycophenolate Mofetil for Treatment of Kidney Disease due to Congenital Urinary Tract Disorders in Children. American Journal of Kidney Diseases, 2008, 52, 706-715.	2.1	5
98	BUN: Creatinine Ratio - Definition of the Normal Range in Children. Nephrology Research & Reviews, 2010, 2, 49-52.	0.2	5
99	Circulating factor in FSGS: a black sheep in the suPAR family?. Pediatric Nephrology, 2013, 28, 1151-1152.	0.9	5
100	Variable Presentations of Rare Genetic Renal Interstitial Diseases. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 437-439.	2.2	5
101	Physician Attitudes Toward Living Kidney Donation. Progress in Transplantation, 2019, 29, 78-83.	0.4	5
102	An electronic health record-based strategy to recruit for a Patient Advisory Council for Research: Implications for inclusion. Journal of Clinical and Translational Science, 2020, 4, 69-72.	0.3	5
103	Health-Related Quality of Life in Focal Segmental Glomerular Sclerosis and Minimal Change Disease: A Qualitative Study of Children and Adults to Inform Patient-Reported Outcomes. Kidney Medicine, 2021, 3, 484-497.e1.	1.0	5
104	Melamine Nephrotoxicity is Mediated by Hyperuricemia. Biomedical and Environmental Sciences, 2015, 28, 904-12.	0.2	5
105	Efficacy and Safety of Immunosuppressive Therapy in Primary Focal Segmental Glomerulosclerosis: A Systematic Review and Meta-analysis. Kidney Medicine, 2022, 4, 100501.	1.0	5
106	Nephrotic-range proteinuria in a child with retinoic acid syndrome. Pediatric Nephrology, 2012, 27, 485-488.	0.9	4
107	Restless Legs Syndrome in Pediatric Patients With Nephrotic Syndrome. Global Pediatric Health, 2015, 2, 2333794X1558599.	0.3	4
108	FP129NEWLY ADMINISTERED IMMUNOSUPPRESSIVE THERAPY (IST) HAS NO IMPACT ON LONG-TERM ANTIPROTEINURIC EFFECT OF SPARSENTAN (SPAR), A DUAL ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONIST, IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): INTERIM ANALYSIS OF THE DUET TRIAL. Nephrology Dialysis Transplantation, 2018, 33, i20-i20.	0.4	4

#	Article	IF	Citations
109	Knowledge and use of recruitment support tools among study coordinators at an academic medical center: The Novel Approaches to Recruitment Planning Study. Contemporary Clinical Trials Communications, 2019, 15, 100424.	0.5	4
110	SUN-037 NO IMPACT OF NEWLY INITIATED IMMUNOSUPPRESSIVE THERAPY OBSERVED ON LONG-TERM ANTIPROTEINURIC EFFECT OF SPARSENTAN IN FOCAL SEGMENTAL GLOMERULOSCLEROSIS: INTERIM 84-WEEK ANALYSIS OF THE DUET TRIAL. Kidney International Reports, 2019, 4, S168-S169.	0.4	4
111	Innovating and invigorating the clinical trial infrastructure for glomerular diseases. Kidney International, 2021, 99, 519-523.	2.6	4
112	A pediatric gateway initiative for glomerular disease: introducing PIONEER. Kidney International, 2021, 99, 515-518.	2.6	4
113	Morning Report: Is the Time Ripe for a Change?. Teaching and Learning in Medicine, 2012, 24, 163-164.	1.3	3
114	The Grand Challenge of Nephrology. Frontiers in Medicine, 2014, 1, 28.	1.2	3
115	suPAR and Team Nephrology. BMC Medicine, 2014, 12, 82.	2.3	3
116	Center Volume and Kidney Transplant Outcomes in Pediatric Patients. Kidney Medicine, 2020, 2, 297-306.	1.0	3
117	APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis. Pediatric Nephrology, 2021, 36, 2747-2757.	0.9	3
118	Provider perspectives on treatment decision-making in nephrotic syndrome. Nephrology Dialysis Transplantation, 2017, 32, i106-i114.	0.4	2
119	Investigational drugs in development for focal segmental glomerulosclerosis. Expert Opinion on Investigational Drugs, 2017, 26, 945-952.	1.9	2
120	Data monitoring committees and stopping trialsâ€"Giving participants a voice. Contemporary Clinical Trials, 2018, 68, 146.	0.8	2
121	Data monitoring committees and randomized clinical trials. Kidney International, 2019, 95, 992.	2.6	2
122	Persistent Disease Activity in Patients With Long-Standing Glomerular Disease. Kidney International Reports, 2020, 5, 860-871.	0.4	2
123	MO126CLINICAL AND BIOMARKER CHARACTERISTICS OF PATIENTS WITH C3G OR IC-MPGN ENROLLED IN TWO PHASE II STUDIES INVESTIGATING THE FACTOR D INHIBITOR DANICOPAN*. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	2
124	Gluten-Free Diet in Childhood Difficult-to-Treat Nephrotic Syndrome: A Pilot Feasibility Study. Glomerular Diseases, 2022, 2, 176-183.	0.2	2
125	Biomarkers of therapeutic response in primary nephrotic syndrome. Pediatric Nephrology, 2013, 28, 159-159.	0.9	1
126	Busy Bs. Journal of the American Society of Nephrology: JASN, 2016, 27, 1584-1586.	3.0	1

#	Article	IF	Citations
127	Interstitial nephritis: Two pediatric cases with atypical radiological features. Radiology Case Reports, 2018, 13, 1003-1006.	0.2	1
128	Association Between Perfluoroalkyl Substance Exposure and Renal Function in Children With CKD Enrolled in H3Africa Kidney Disease Research Network. Kidney International Reports, 2019, 4, 1641-1645.	0.4	1
129	The Psychosocial Impact of a Diagnosis of Hypertension in Pediatric Patients. Kidney International Reports, 2020, 5, 228-230.	0.4	1
130	Effect of a Gluten-Free Diet on Albuminuria in Children with Newly Diagnosed Celiac Disease. Complex Psychiatry, 2021, 1, 3-9.	1.3	1
131	Profiling Clinical Research Activity at an Academic Medical Center by Using Institutional Databases: Content Analysis. JMIR Public Health and Surveillance, 2020, 6, e12813.	1.2	1
132	Determinants of medication adherence in childhood nephrotic syndrome and associations of adherence with clinical outcomes. Pediatric Nephrology, 2022, 37, 1585-1595.	0.9	1
133	Urinary Polycyclic Aromatic Hydrocarbons in a Longitudinal Cohort of Children with CKD: A Case of Reverse Causation?. Kidney360, 2022, 3, 1011-1020.	0.9	1
134	Un-Locke-ing Neuroethical Dilemmas. AJOB Neuroscience, 2011, 2, 52-54.	0.6	0
135	Hemolytic uremic syndrome: sound minds, sick kidneys. Developmental Medicine and Child Neurology, 2013, 55, 687-688.	1.1	0
136	Drugs and Trials: Lessons From Plato. Clinical Therapeutics, 2013, 35, 688-691.	1.1	0
137	Recurrent focal segmental glomerulosclerosis after kidney transplantation: response to comments by Straatmann and Vehaskari. Pediatric Nephrology, 2016, 31, 1377-1377.	0.9	0
138	Traveling in Other People×3s Shoes. Current Problems in Pediatric and Adolescent Health Care, 2016, 46, 158-159.	0.8	0
139	Does What Goes Around Always Come Around?. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1788-1790.	2.2	0
140	Tonsillectomy for the Management of Immunoglobulin A Nephropathy. JAMA Network Open, 2019, 2, e194755.	2.8	0
141	Research imperative. Contemporary Clinical Trials Communications, 2019, 14, 100350.	0.5	0
142	Pulmonary Manifestations of Renal Disorders in Children. Pediatric Clinics of North America, 2021, 68, 209-222.	0.9	0
143	Title is missing!. , 2020, 17, e1003384.		0
144	Title is missing!. , 2020, 17, e1003384.		0

#	Article	IF	Citations
145	Title is missing!. , 2020, 17, e1003384.		0
146	Title is missing!. , 2020, 17, e1003384.		0
147	Title is missing!. , 2020, 17, e1003384.		0